SG11201606275WA - Combination of baclofen, acamprosate and medium chain triglycerides for the treatment of neurological disorders - Google Patents
Combination of baclofen, acamprosate and medium chain triglycerides for the treatment of neurological disordersInfo
- Publication number
- SG11201606275WA SG11201606275WA SG11201606275WA SG11201606275WA SG11201606275WA SG 11201606275W A SG11201606275W A SG 11201606275WA SG 11201606275W A SG11201606275W A SG 11201606275WA SG 11201606275W A SG11201606275W A SG 11201606275WA SG 11201606275W A SG11201606275W A SG 11201606275WA
- Authority
- SG
- Singapore
- Prior art keywords
- acamprosate
- baclofen
- treatment
- combination
- medium chain
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461938340P | 2014-02-11 | 2014-02-11 | |
| PCT/EP2015/052694 WO2015121218A1 (en) | 2014-02-11 | 2015-02-10 | Combination of baclofen, acamprosate and medium chain triglycerides for the treatment of neurological disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201606275WA true SG11201606275WA (en) | 2016-08-30 |
Family
ID=52544464
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201606275WA SG11201606275WA (en) | 2014-02-11 | 2015-02-10 | Combination of baclofen, acamprosate and medium chain triglycerides for the treatment of neurological disorders |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US10905672B2 (en) |
| EP (1) | EP3104850A1 (en) |
| JP (1) | JP6619744B2 (en) |
| KR (1) | KR20160111013A (en) |
| CN (1) | CN106456583B (en) |
| AU (1) | AU2015217796B2 (en) |
| CA (1) | CA2938361A1 (en) |
| EA (1) | EA201691602A1 (en) |
| IL (1) | IL246856A0 (en) |
| MX (1) | MX2016010409A (en) |
| SG (1) | SG11201606275WA (en) |
| WO (1) | WO2015121218A1 (en) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3104850A1 (en) | 2014-02-11 | 2016-12-21 | Pharnext | Combination of baclofen, acamprosate and medium chain triglycerides for the treatment of neurological disorders |
| JP7026347B2 (en) | 2015-05-04 | 2022-02-28 | コンフルーエンス ファーマシューティカルズ，エルエルシー | Acamprosate sprinkle formulation |
| US20180008612A1 (en) * | 2016-07-11 | 2018-01-11 | Taho Pharmaceuticals Ltd. | Transdermal delivery system containing galantamine or salts thereof |
| CA3056614C (en) | 2017-03-15 | 2023-09-26 | Cerecin Inc. | Pharmaceutical compositions having high drug loadings of medium chain triglycerides and methods related thereto |
| JP2020519669A (en) * | 2017-05-17 | 2020-07-02 | コンフルーエンス ファーマシューティカルズ，エルエルシー | Preparation of homotaurine and its salt |
| US20210236445A1 (en) * | 2018-01-29 | 2021-08-05 | Pharnext | Baclofen and acamprosate based therapy of alzheimer's disease in patients having lost responsiveness to acetylcholinesterase inhibitor therapy |
| KR20200132950A (en) * | 2018-03-15 | 2020-11-25 | 세레신 인코포레이티드 | Pharmaceutical compositions with high drug loading medium chain triglycerides and methods related thereto |
| CN111166868A (en) * | 2019-07-17 | 2020-05-19 | 江苏西宏生物医药有限公司 | A composition for treating neurological diseases and disorders |
| KR20210072569A (en) * | 2019-12-09 | 2021-06-17 | 주식회사 종근당 | Complex formulation comprising donepezil and memantine |
| EP4153307A1 (en) * | 2020-05-19 | 2023-03-29 | Société des Produits Nestlé S.A. | Mct formulations for improving cognitive functions |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2323940T3 (en) * | 2000-05-01 | 2009-07-28 | Accera, Inc. | USE OF MEDIUM CHAIN TRIGLICERIDS FOR THE TREATMENT AND PREVENTION OF ALZHEIMER'S DISEASE. |
| US6927036B2 (en) | 2002-02-19 | 2005-08-09 | Xero Port, Inc. | Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof |
| KR101140559B1 (en) | 2003-08-20 | 2012-07-05 | 제노포트 인코포레이티드 | Acyloxyalkyl carbamate prodrugs, methods of synthesis and use |
| EP1716115B1 (en) | 2003-12-30 | 2013-02-27 | XenoPort, Inc. | Synthesis of acyloxyalkyl carbamate prodrugs and intermediates thereof |
| EP2117517B1 (en) | 2007-01-11 | 2011-06-01 | XenoPort, Inc. | Sustained release oral dosage forms of a prodrug of r-baclofen and methods of treatment |
| WO2009005519A1 (en) * | 2007-06-29 | 2009-01-08 | Accera, Inc. | Combinations of medium chain triglycerides and therapeutic agents for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism |
| WO2009033079A1 (en) | 2007-09-07 | 2009-03-12 | Xenoport, Inc. | Externally masked neopentyl sulfonyl ester cyclization release prodrugs of acamprosate, compositions thereof, and methods of use |
| US8168617B2 (en) | 2007-09-07 | 2012-05-01 | Xenoport, Inc. | Complex pantoic acid ester neopentyl sulfonyl ester cyclization release prodrugs of acamprosate, compositions thereof, and methods of use |
| MX2010003501A (en) * | 2007-10-04 | 2010-06-09 | Bio Architecture Lab Inc | Biofuel production. |
| TW200932734A (en) | 2007-10-15 | 2009-08-01 | Xenoport Inc | Internally masked neopentyl sulfonyl ester cyclization release prodrugs of acamprosate, compositions thereof, and methods of use |
| WO2009061934A1 (en) | 2007-11-06 | 2009-05-14 | Xenoport, Inc. | Use of prodrugs of gaba b agonists for treating neuropathic and musculoskeletal pain |
| EP2065038A1 (en) | 2007-11-30 | 2009-06-03 | Pharnext | New therapeutic approaches for treating Charcot-Marie-Tooth disease |
| WO2009096985A1 (en) | 2008-02-01 | 2009-08-06 | Xenoport, Inc. | Sustained release particulate oral dosage forms of (r)-baclofen prodrugs and methods of treatment |
| US20100137442A2 (en) | 2008-02-01 | 2010-06-03 | Xenoport, Inc. | Sustained Release Particulate Oral Dosage Forms of (R)-Baclofen and Methods of Treatment |
| NZ589304A (en) | 2008-04-29 | 2012-03-30 | Pharnext | Combination compositions for treating alzheimer disease and related disorders with zonisamide and acamprosate |
| CN102065897B (en) | 2008-04-29 | 2013-11-13 | 法奈科斯公司 | New therapeutic approaches for treating alzheimer disease and related disorders through a modulation of cell stress response |
| DK2282778T3 (en) | 2008-04-29 | 2017-05-01 | Pharnext | NEW THERAPEUTIC APPROACHES TO TREAT ALZHEIMER'S DISEASE AND RELATED DISEASES THROUGH A MODULATION OF ANGIOGENIC |
| EP2135607A1 (en) | 2008-06-18 | 2009-12-23 | Pharnext | Combination of pilocarpin and methimazol for treating Charcot-MarieTooth disease and related disorders |
| NZ594648A (en) | 2009-03-03 | 2013-12-20 | Xenoport Inc | Sustained release oral dosage forms of an r-baclofen prodrug |
| JP2012524065A (en) | 2009-04-17 | 2012-10-11 | ゼノポート，インコーポレーテッド | Γ-aminobutyric acid derivatives as GABAB receptor ligands |
| EP2263665A1 (en) | 2009-06-02 | 2010-12-22 | Pharnext | New compositions for treating CMT and related disorders |
| US9393241B2 (en) | 2009-06-02 | 2016-07-19 | Pharnext | Compositions for treating CMT and related disorders |
| EP2322163A1 (en) | 2009-11-03 | 2011-05-18 | Pharnext | New therapeutics approaches for treating alzheimer disease |
| US9387206B2 (en) | 2009-11-03 | 2016-07-12 | Pharnext | Therapeutic approaches for treating Alzheimer's disease |
| ES2532006T3 (en) | 2009-11-20 | 2015-03-23 | Pharnext | New diagnostic tools for Charcot-Marie-Tooth disease |
| ES2640777T3 (en) * | 2009-12-30 | 2017-11-06 | Baylor Research Institute | Anaplerotic therapy for Alzheimer's disease |
| US9248111B2 (en) | 2011-03-01 | 2016-02-02 | Pharnext | Therapeutic approaches for treating parkinson's disease |
| US10010515B2 (en) | 2011-03-01 | 2018-07-03 | Pharnext | Therapeutic approaches for treating Parkinson's disease |
| US9241933B2 (en) | 2011-03-01 | 2016-01-26 | Pharnext | Compositions for treating amyotrophic lateral sclerosis |
| SI2796132T1 (en) | 2011-03-01 | 2018-09-28 | Pharnext | Baclofen and acamprosate based therapy of neurological disorders |
| UA113165C2 (en) | 2011-03-01 | 2016-12-26 | APPLICATION OF A COMBINATION OF Baclofen AND ACOMPROSAT FOR THE TREATMENT OF NEUROLOGICAL DISEASES AND A COMPOSITION CONTAINING Baclofen AND ACAMPROSAT | |
| US9867837B2 (en) | 2011-03-01 | 2018-01-16 | Pharnext | Compositions for treating neurological disorders |
| EP2705842A1 (en) | 2012-09-05 | 2014-03-12 | Pharnext | Therapeutic approaches for treating parkinson's disease |
| US9931326B2 (en) | 2011-03-29 | 2018-04-03 | Pharnext | Composition comprising torasemide and baclofen for treating neurological disorders |
| CA2879114A1 (en) | 2012-07-18 | 2014-01-23 | Pharnext | Baclofen and acamprosate based therapy of macular degeneration disorders |
| EP2705841A1 (en) | 2012-09-05 | 2014-03-12 | Pharnext | Combinations of nootropic agents for treating cognitive dysfunctions |
| EP2705843A1 (en) | 2012-09-05 | 2014-03-12 | Pharnext | Therapeutic approaches for treating epilepsy and related disorders through reduction of epileptogenesis |
| EP2727587A1 (en) | 2012-10-30 | 2014-05-07 | Pharnext | Compositions, methods and uses for the treatment of diabetes and related conditions by controlling blood glucose level |
| CA2913331C (en) | 2013-06-05 | 2021-08-24 | Pharnext | Stable oral solutions for combined api |
| WO2015063140A1 (en) | 2013-10-30 | 2015-05-07 | Pharnext | Compositions, methods and uses for the treatment of diabetes and related conditions by controlling blood glucose level |
| EP3104850A1 (en) | 2014-02-11 | 2016-12-21 | Pharnext | Combination of baclofen, acamprosate and medium chain triglycerides for the treatment of neurological disorders |
| US9700036B1 (en) | 2015-04-08 | 2017-07-11 | Justin P. Chatelain | Duck decoy device |
| US9700037B1 (en) | 2014-09-08 | 2017-07-11 | Justin P. Chatelain | Duck decoy device |
-
2015
- 2015-02-10 EP EP15705551.8A patent/EP3104850A1/en not_active Withdrawn
- 2015-02-10 KR KR1020167025118A patent/KR20160111013A/en not_active Application Discontinuation
- 2015-02-10 AU AU2015217796A patent/AU2015217796B2/en not_active Ceased
- 2015-02-10 SG SG11201606275WA patent/SG11201606275WA/en unknown
- 2015-02-10 US US15/117,774 patent/US10905672B2/en active Active
- 2015-02-10 WO PCT/EP2015/052694 patent/WO2015121218A1/en active Application Filing
- 2015-02-10 EA EA201691602A patent/EA201691602A1/en unknown
- 2015-02-10 CA CA2938361A patent/CA2938361A1/en not_active Abandoned
- 2015-02-10 MX MX2016010409A patent/MX2016010409A/en unknown
- 2015-02-10 JP JP2016551144A patent/JP6619744B2/en not_active Expired - Fee Related
- 2015-02-10 CN CN201580008144.4A patent/CN106456583B/en not_active Expired - Fee Related
-
2016
- 2016-07-20 IL IL246856A patent/IL246856A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL246856A0 (en) | 2016-08-31 |
| US10905672B2 (en) | 2021-02-02 |
| WO2015121218A1 (en) | 2015-08-20 |
| JP2017505786A (en) | 2017-02-23 |
| CN106456583A (en) | 2017-02-22 |
| JP6619744B2 (en) | 2019-12-11 |
| KR20160111013A (en) | 2016-09-23 |
| CN106456583B (en) | 2020-04-07 |
| EA201691602A1 (en) | 2017-03-31 |
| AU2015217796A1 (en) | 2016-08-18 |
| AU2015217796B2 (en) | 2020-04-30 |
| EP3104850A1 (en) | 2016-12-21 |
| CA2938361A1 (en) | 2015-08-20 |
| US20160354335A1 (en) | 2016-12-08 |
| MX2016010409A (en) | 2016-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL289650A (en) | Azolopyrimidine for the treatment of cancer-related disorders | |
| IL288712B1 (en) | Methods for the treatment of abnormal involuntary movement disorders | |
| IL246856A0 (en) | Combination of baclofen, acamprosate and medium chain triglycerides for the treatment of neurological disorders | |
| IL255185A0 (en) | 1-heteroaryl-indoline-4-carboxamides as modulators of gpr52 useful for the treatment or prevention of disorders related thereto | |
| HK1252996A1 (en) | Methods for the treatment of epilepsy | |
| SG11201708181RA (en) | Methods for the treatment of inflammatory disorders | |
| LT3229790T (en) | Compositions comprising medium chain triglycerides for use in the treatment of epilepsy | |
| HK1250624A1 (en) | Methods for the treatment of cardiovascular disorders | |
| ZA201700037B (en) | Compounds for the treatment of seizures and other central nervous system disorders and conditions | |
| SG11201706952VA (en) | Compositions and methods for the treatment of epilepsy and neurological disorders | |
| GB201521543D0 (en) | Methods for the treatment of inflammatory disorders | |
| GB201513993D0 (en) | Methods for the treatment of inflammatory disorders | |
| GB201521542D0 (en) | Methods for the treatment of cardiovascular disorders | |
| GB201513345D0 (en) | Methods for the treatment of Inflammatory disorders | |
| GB201507113D0 (en) | Methods for the treatment of inflammatory disorders | |
| GB201506419D0 (en) | Methods for the treatment of inflammatory disorders | |
| GB201506229D0 (en) | Methods For the Treatment Of Inflammatory Disorders | |
| GB201513991D0 (en) | Methods for the treatment of cardiovascular disorders | |
| GB201513344D0 (en) | Methods for the treatment of Cardiovascular disorders | |
| GB201507109D0 (en) | Methods for the treatment of cardiovascular disorders | |
| AU2014902257A0 (en) | Treatment of immune disorders 2 | |
| GB201413533D0 (en) | Combination therapy for treating disorders of the vestibular system |